PERSONALIZED COVID-19 DIAGNOSTICS WITH IMMUNOPLASMONIC MICROSCOPY

利用免疫等离子显微镜进行个性化 COVID-19 诊断

• 批准号: 555170-2020
• 负责人: Meunier, Michel
• 金额: $ 3.64万
• 依托单位: École Polytechnique de Montréal
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=705779
• 关键词: PERSONALIZED; COVID; 19; DIAGNOSTICS; IMMUNOPLASMONIC

At this time, healthcare system is facing heavy challenges requiring new and urgent tools to handle and relief severe impacts of COVID-19 outbreak. Personalized access to affordable, high-quality diagnostic tools for the detection of infectious diseases, including SARS-CoV-2, in resource-limited settings and outside the hospital environment, is imperative. In this project, we propose an alternative and promising solution for rapid clinical and personalized COVID-19 diagnosis. High efficiency and sensitivity of the proposed device is ensured by the use of an elaborated Imaging Localized Surface Plasmon Resonance (ILSPR) biosensing technology. The key innovation here is the dual utilization of specifically functionalized proprietary own immunoplasmonic nanoparticles (NPs). Due to their unique optical and chemical properties, plasmonic NPs, which are precisely functionalized by specific biomolecules can perform as (I) selective biomarkers of target viruses (i.e., the detection of expressed spike proteins), and as (II) optically active tags easily detectable and quantifiable under our simplified optical imaging system (i.e., dark-field side-illumination microscopy developed in our laboratory). Our well-organized research team, including, chemists, biologists, engineers, and clinical biochemist from the Maisonneuve-Rosemont Hospital with a collaboration of the innovation company (Allied Scientific Medical) joint their efforts to develop a professional cost-effective, plasmonic biosensing system to diagnose patients outside of centralized facilities. Taking advantage of the widespread distribution of personal electronic devices (i.e., smartphones and tablets) equipped with an effective optical sensor and communication capability, the proposed ILSPR plasmonic biosensor can also be considered as the hand-held portable personalized diagnostic device capable to obtain accurate results in less than 10 minutes and dispatches it to specialists for a precise analysis or confirmation through a telemedicine network.

目前，医疗保健系统正面临严峻挑战，需要新的紧急工具来处理和缓解 COVID-19 爆发的严重影响。在资源有限的环境和医院环境之外，必须提供个性化的、负担得起的、高质量的诊断工具来检测传染病，包括 SARS-CoV-2。在这个项目中，我们提出了一种替代且有前途的解决方案，用于快速临床和个性化 COVID-19 诊断。通过使用精心设计的成像局部表面等离子共振（ILSPR）生物传感技术，确保了所提出设备的高效率和灵敏度。这里的关键创新是双重利用特殊功能化的专有免疫等离子纳米颗粒（NP）。由于其独特的光学和化学特性，由特定生物分子精确功能化的等离子体纳米粒子可以作为（I）目标病毒的选择性生物标志物（即，检测表达的刺突蛋白），以及（II）轻松地作为光学活性标签在我们简化的光学成像系统（即我们实验室开发的暗场侧照明显微镜）下可检测和量化。我们组织严密的研究团队，包括来自 Maisonneuve-Rosemont 医院的化学家、生物学家、工程师和临床生物化学家，与创新公司 (Allied Scientific Medical) 合作，共同努力开发专业的、具有成本效益的等离子体生物传感系统在集中设施之外诊断患者。利用配备有效光学传感器和通信能力的个人电子设备（即智能手机和平板电脑）的广泛分布，所提出的ILSPR等离子体生物传感器也可以被视为能够获得准确结果的手持式便携式个性化诊断设备不到10分钟即可通过远程医疗网络发送给专家进行精确分析或确认。